An important drug in Novartis AG’s respiratory pipeline has been sidelined in the U.S. by FDA’s crackdown on the safety of long-acting beta2-adrenergic agonists, but during an April 24 quarterly earnings call, management said it has made progress on the regulatory strategy for QVA149.
The drug is a combination product containing Novartis’ marketed LABA indacaterol and investigational long-acting muscarinic antagonist (LAMA) NVA237 (glycopyrronium bromide)....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?